Disease · MONDO_0006196

endometrial serous adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endometrial serous adenocarcinoma. Diseases, record MONDO_0006196. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006196

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endometrial serous adenocarcinoma; Open Targets
Open Targets ID: MONDO_0006196; Open Targets
Other names: body of uterus serous adenocarcinoma, serous endometrial adenocarcinoma, uterine corpus serous adenocarcinoma, uterine papillary serous carcinoma, uterine serous adenocarcinoma, uterine serous carcinoma, uterine serous papillary adenocarcinoma; Open Targets
Disease Ontology: DOID:5750; Disease Ontology
NCI Thesaurus: C27838; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZENOSERTIB	CHEMBL5095036	Small molecule	Phase 2	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets
ADAVOSERTIB	CHEMBL1976040	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIRAPARIB	CHEMBL1094636	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AFATINIB	CHEMBL1173655	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ERBB2	Receptor tyrosine-protein kinase erbB-2	2	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
WEE1	Wee1-like protein kinase	2	Serine/threonine-protein kinase WEE1 inhibitor	Phase 2	https://conductscience.org/library/genes/7465	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 1/2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 1/2	https://conductscience.org/library/genes/613	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/1588	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB4	Receptor tyrosine-protein kinase erbB-4	1	Receptor protein-tyrosine kinase erbB-4 inhibitor	Phase 2	https://conductscience.org/library/genes/2066	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2/3	https://conductscience.org/library/genes/2280	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets
PARP1	Poly [ADP-ribose] polymerase 1	1	Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/142	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00942357	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Phase 3	813	2018-12-19	Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7	CARBOPLATIN, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04590248	A Study of Adavosertib as Treatment for Uterine Serous Carcinoma	Phase 2	109	2023-08-14	Uterine Serous Carcinoma	ADAVOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT00231868	A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma	Phase 2	81	2020-08-12	Uterine Cancer	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01367002	Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer	Phase 2	61	2023-04-18	Endometrial Cancer	CARBOPLATIN, PACLITAXEL, TRASTUZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00506779	Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma	Phase 1/2	17	2020-11-18	Uterine Cancer	IMATINIB MESYLATE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02112552	Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer	Phase 2	4	2023-08-29	Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04158336	A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors	Phase 1	274		Solid Tumor	AZENOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT04814108	A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma	Phase 2	92		Uterine Serous Carcinoma	AZENOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT02491099	A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma	Phase 2	50		HER2/Neu+ Uterine Serous Carcinoma	AFATINIB	Its record names the disease	ClinicalTrials.gov
NCT03668340	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Phase 2	49		Uterine Cancer	ADAVOSERTIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): Number of Participants With Recurrence, Progression or Death	132 of 370	139 of 366	736	NCT00942357	Trial comparisons
Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): serious adverse events	78 of 346	61 of 361	707	NCT00942357	Trial comparisons
Carboplatin/Paclitaxel vs Trastuzumab: deaths from any cause	21 of 28	21 of 32	60	NCT01367002	Trial comparisons
Carboplatin/Paclitaxel vs Trastuzumab: serious adverse events	6 of 28	14 of 32	60	NCT01367002	Trial comparisons
Carboplatin/Paclitaxel vs Trastuzumab: To Assess Overall Survival (OS)	7 of 28	9 of 30	58	NCT01367002	Trial comparisons
Participants With Measurable Disease vs Participants With Non-Measurable Disease: Number of Participants With Complete Response	1 of 8	7 of 8	16	NCT00506779	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32601075	RESULT	1	PubMed
29584549	RESULT	1	PubMed
25268372	RESULT	1	PubMed
23636398	RESULT	1	PubMed
23359684	RESULT	1	PubMed
22035806	RESULT	1	PubMed
15894362	RESULT	1	PubMed
15746676	RESULT	1	PubMed
12006548	RESULT	1	PubMed
40262070	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006196

GET https://conductscience.org/api/diseases/v1/MONDO_0006196/targets?page=2

API reference For AI assistants